Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Agriculture Fund (DBA) vs Summit Therapeutics Inc (SMMT) Price & Performance

Invesco DB Agriculture FundTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Agriculture Fund vs Summit Therapeutics Inc — how do they compare? Invesco DB Agriculture Fund trades at $27.79, while Summit Therapeutics Inc trades at $15.27 (market cap $12.06B). The key difference: Invesco DB Agriculture Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

DBASMMT
52-Week High
$28.73$26.98
52-Week Low
$25.44$12.55
Market Cap
$12.06B
Sector
Health
Enterprise Value
$11.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Agriculture Fund

DBA trades at $27.69, down 0.47% today, but maintains a strong technical bullish signal with moving averages indicating positive momentum. The fund has outperformed the S&P 500 recently, gaining 5% in July 2026, driven by strength in agricultural commodities. It consolidates near highs with a bullish trend established since 2020, supported by a 3.25% yield.

The outlook remains positive given favorable agricultural market dynamics and geopolitical factors supporting commodity prices. Key risks include sector volatility, management fees, and sensitivity to global crop conditions and trade policies. The fund offers diversified exposure to agricultural futures as a hedge against inflation and supply disruptions.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.

Returns comparison

Trailing returns across standard periods

About Invesco DB Agriculture Fund

The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.

Read more on DBA

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT